DPYD and neoplasm: Given that IRIS (irinotecan/S-1) regimens based on the DPD inhibitor fluoropyrimidine may be more effective against DPD-high tumors than FOLFIRI, this finding is consistent with a recent clinical study, which suggested that patients previously treated with oxaliplatin-based chemotherapy better responded to IRIS than to FOLFIRI.[9, 10] Second, we found that administering bevacizumab to patients raised their VEGFA expression levels, supporting that bevacizumab encourages VEGFA mRNA expression from tumor cells via feedback or alternative unknown mechanisms.